Endocrine Abstracts

Introduction: Poor metabolic control in type 1 diabetes mellitus (T1DM) is associated with micro and macrovascular complications. The implementation of interstitial glucose monitoring systems has contributed to the improvement of glycemic control in recent years.

Objectives: Our main objective was to analyze the results of implementing flash glucose monitoring (FGM) devices after 1 year, and see if it managed to improve glycemic control in our patients.

Material and Methods: Cross-sectional observational study in people with T1DM, carriers of the FGM devices, with follow-up at Hospital of Antequera (Malaga, Spain) during the first year since the establishment of a specific medical consultation. We collect the HbA1c prior to the start of FGM, HbA1c a year after FGM, average glucose, time in range, and glucose management indicator (GMI). The analysis has been carried out using the JAMOVI program.

Results: 154 patients were included, 41.2% women, mean age 40.8±14.7 years, mean evolution time 18.9±11.5 years, 18.9% presented diabetic retinopathy, 15.5% presented diabetic neuropathy, 27% presented high blood presure, 39.2% associated dyslipidemia. The HbA1c prior to the use of FGM is 8.13% and one year after the use of FGM is 7.65% (P<0.01). The average glucose from the FGM is 170±47.6 mg/dl, variability 36.6±8.22%, GMI 7.33±1.34%, time-in-range (TIR) 54.8±21.1%, reaching a TIR above 70% in 27.5% of the patients, use of the sensor of 86.2±18.6%.

Conclusions: The use of FGM has improved glycemic control in people with T1DM being followed up at the Endocrinology consultation at the Hospital of Antequera.